Q-omics provides the consensus-scored MIR4477A profile across patient tissues and cancer cell-line models. MIR4477A expression is associated with patient survival in 12 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, MIR4477A is differentially expressed in 4, with the highest sampling consensus in BRCA. Additionally, MIR4477A RNA expression shows 5,642 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight UVM, BRCA, and STAD as cancer lineages where MIR4477A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MIR4477A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MIR4477A survival associations across molecular data types. MIR4477A RNA expression shows survival associations in the most cancer types (12). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MIR4477A RNA expression–survival associations across cancer types. High MIR4477A expression shows unfavorable associations in UVM, CESC, ESCA, LIHC and KIRC, but favorable associations in UCS. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for MIR4477A RNA expression.
This table summarizes MIR4477A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for MIR4477A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MIR4477A shows higher tumor expression in BRCA, LUSC, LIHC and LUAD. The BRCA box plot shows higher MIR4477A RNA expression in tumor versus normal tissue (log2 FC = +0.194, t-test p < 0.001).
This table shows molecular features associated with MIR4477A in patient tissues and cancer cell lines. In patient samples, MIR4477A shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
